| Literature DB >> 21179575 |
Cristina Mitea1, Elma M J Salentijn, Peter van Veelen, Svetlana V Goryunova, Ingrid M van der Meer, Hetty C van den Broeck, Jorge R Mujico, Veronica Montserrat, Veronica Monserrat, Luud J W J Gilissen, Jan Wouter Drijfhout, Liesbeth Dekking, Frits Koning, Marinus J M Smulders.
Abstract
Celiac disease is caused by an uncontrolled immune response to gluten, a heterogeneous mixture of wheat storage proteins, including the α-gliadins. It has been shown that α-gliadins harbor several major epitopes involved in the disease pathogenesis. A major step towards elimination of gluten toxicity for celiac disease patients would thus be the elimination of such epitopes from α-gliadins. We have analyzed over 3,000 expressed α-gliadin sequences from 11 bread wheat cultivars to determine whether they encode for peptides potentially involved in celiac disease. All identified epitope variants were synthesized as peptides and tested for binding to the disease-associated HLA-DQ2 and HLA-DQ8 molecules and for recognition by patient-derived α-gliadin specific T cell clones. Several specific naturally occurring amino acid substitutions were identified for each of the α-gliadin derived peptides involved in celiac disease that eliminate the antigenic properties of the epitope variants. Finally, we provide proof of principle at the peptide level that through the systematic introduction of such naturally occurring variations α-gliadins genes can be generated that no longer encode antigenic peptides. This forms a crucial step in the development of strategies to modify gluten genes in wheat so that it becomes safe for celiac disease patients. It also provides the information to design and introduce safe gluten genes in other cereals, which would exhibit improved quality while remaining safe for consumption by celiac disease patients.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21179575 PMCID: PMC3002971 DOI: 10.1371/journal.pone.0015637
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Amino acid sequences of α-gliadin derived peptides.
| Immune response | Restriction element | Core-Sequence | |
| DQ2-Glia-α1 | Adaptive | HLA-DQ2 | P{F/Y}PQPQLPY |
| DQ2-Glia-α2 | Adaptive | HLA-DQ2 | PQPQLPYPQ |
| DQ2-Glia- α3 | Adaptive | HLA-DQ2 | FRPQQPYPQ |
| DQ8-Glia-α1 | Adaptive | HLA-DQ8 | QGSFQPSQQ |
| P31-43 | Innate | not applicable | PGQQQPFPPQQPY |
Five antigenic peptides derived from α-gliadins are known to be involved in celiac decease. For the peptides that can provoke an adaptive immune response in CD patients (HLA-DQ2 restricted or HLA-DQ8 restricted) the minimal 9-mer “canonical” epitope cores are shown. One peptide, p31-43, is known to be involved in an innate immune response observed in CD. For each of the epitopes is specified the name, which immune response it evokes, the restriction element and the amino acid sequence.
HLA-DQ2-Glia-α1 epitope variants expressed in bread wheat.
|
|
|
| N | |
|
| 466 | 520 | 986 | |
|
| 93 | 93 | ||
|
| 106 | 106 | ||
|
| 94 | 94 | ||
|
| 7 | 54 | 61 | |
|
| 29 | 29 | ||
|
| 6 | 6 | ||
| Total | 673 | 702 | 1375 |
Expressed variants of the DQ2-Glia-α1 epitope represented by ≥5 transcripts and the number of transcripts per epitope variants per chromosomal locus (Gli-A2, Gli-B2 or Gli-D2). N = total transcript count per variant. In bold: amino acid variation.
DQ2-Glia-α2 epitope variants expressed in bread wheat.
|
|
|
| N | |
|
| 607 | 607 | ||
|
| 431 | 431 | ||
|
| 382 | 382 | ||
|
| 106 | 106 | ||
|
| 31 | 31 | ||
|
| 85 | 85 | ||
|
| 54 | 54 | ||
|
| 30 | 30 | ||
|
| 29 | 29 | ||
|
| 7 | 7 | ||
|
| 6 | 6 | ||
|
| 6 | 6 | ||
| Total | 629 | 419 | 726 | 1774 |
Expressed variants of the DQ2-Glia-α2 epitope represented by ≥5 transcripts and the number of transcripts per epitope variants per chromosomal locus (Gli-A2, Gli-B2 or Gli-D2). N = total transcript count per variant. In bold: amino acid variation.
DQ2-Glia-α3 epitope variants expressed in bread wheat.
|
|
|
| N | |
|
| 650 | 449 | 1099 | |
|
| 732 | 687 | 606 | 2025 |
|
| 179 | 8 | 187 | |
|
| 157 | 157 | ||
|
| 148 | 148 | ||
|
| 56 | 56 | ||
|
| 18 | 18 | ||
|
| 20 | 20 | ||
|
| 13 | 13 | ||
|
| 8 | 8 | ||
|
| 6 | 6 | ||
| Total | 1395 | 1108 | 1234 | 3737 |
Expressed variants of the DQ2-Glia-α3 epitope represented by ≥5 transcripts and the number of transcripts per epitope variants per chromosomal locus (Gli-A2, Gli-B2 or Gli-D2). : DQ2-Glia-α3 variants located on the position of the innate responsive element, p31-43. N = total transcript count per variant. In bold: amino acid variation.
DQ8-Glia-α1 epitope variants expressed in bread wheat.
|
|
|
| N | |
|
| 186 | 381 | 567 | |
|
| 409 | 409 | ||
|
| 114 | 114 | ||
|
| 103 | 103 | ||
|
| 112 | 112 | ||
|
| 111 | 111 | ||
|
| 4 | 27 | 31 | |
|
| 6 | 6 | ||
| Total | 512 | 413 | 528 | 1453 |
Expressed variants of the DQ8-Glia-α1 epitope, represented by ≥5 transcripts and the number of transcripts per epitope variants per chromosomal locus (Gli-A2, Gli-B2 or Gli-D2). N = total transcript count per variant. In bold: amino acid variation.
T cell proliferation and HLA-DQ2 binding capacity of DQ2-Glia-α variants.
| No. | Peptide | locus | IC50DQ2-Glia-α1 | Glia-α1T cell clone | IC50DQ2-Glia-α2 | Glia-α2T cell clone |
| 1 |
|
| 5 | + | 18 | + |
| 2 |
|
| 5 | + | 34 | + |
| 3 |
|
| 8 | ± | 11 | - |
| 4 |
|
| 12 | - | 24 | - |
| 5 |
|
| 14 | ± | 19 | + |
| 6 |
|
| 21 | + | 21 | - |
| 7 |
|
| 42 | + | 41 | ± |
| 8 |
|
| 7 | ± | 32 | - |
| 9 |
|
| 57 | + | 41 | - |
| 10 |
|
| 67 | + | 24 | - |
| 11 |
|
| 4 | - | 4 | ± |
| 12 |
|
| 8 | - | 8 | + |
| 13 |
|
| 45 | - | 45 | - |
| 14 |
|
| 86 | - | 86 | - |
| 15 |
|
| nd | - | nd | - |
|
|
| |||||
| 16 |
|
| 35 | + | ||
| 17 |
|
| 3080 | - | ||
|
|
| |||||
| 18 |
|
| 16 | + | ||
| 19 |
|
| 33 | - | ||
| 20 |
|
| nd | - |
Variants of the DQ2-Glia-α1 and DQ2-Glia-α2 epitopes as encoded by the α-gliadin transcriptome were synthesized as deamidated 14- to 17-mer peptides (column 1, underlined: DQ2-Glia-α1/α2 epitope region) and tested for stimulation of DQ2-Glia-α1 and DQ2-Glia-α2 specific T cell clones in a proliferation assay. ± = 100 times reduced T cell stimulation compared to the ‘canonical’ epitope; - = 1000 times reduced T cell stimulation compared to the ‘canonical’ epitope. For each epitope shorter versions of the peptide variant, including the putative epitope core flanked by at least two amino acids, were tested in a cell free in vitro peptide binding assay for binding to HLA-DQ2 antigen presenting cells (lysates from HLA-DR3/DQ2 positive EBV-transfored B-cells). IC50 DQ2-Glia-α1/α2 = mean value of the half maximal inhibitory concentration (IC50) returned by the binding assays for respectively DQ2-Glia-α1 and DQ2-Glia-α2 epitope variants. IC50 values were calculated based on the observed competition between the tested peptides and biotin-labelled indicator peptides and indicate the concentration of the tested peptide required for half maximal inhibition of the binding of the indicator peptide.
Figure 1Presence of DQ2-Glia-α1 and DQ2-Glia-α2 epitopes in diploid wheat.
Pepsin-trypsin digests of 29 diploid wheat accessions were prepared and tested in a competition ELISA with a mAb specific for a sequence partially overlapping with the DQ2-Glia-α1 and DQ2-Glia-α2 epitopes and after deamidation with T cell clones specific for the DQ2-Glia-α1 and DQ2-Glia-α2 epitopes. A: results of the competiton ELISA. B: T cell proliferation assay with a DQ2-Glia-α1 specific T cell clone. C: T cell proliferation assay with a DQ2-Glia-α2 specific T cell clone. IL-2: proliferation of the T cell clone under the influence of interleukin-2. Background: proliferation of the T cells in the presence of antigen presenting cells but no antigen. Positive control: proliferation of the T cell clone in the presence of a synthetic peptide encoding the specific α-gliadin epitope and antigen presenting cells. cpm: counts per minute. AA: diploid accessions with an A genome; SS: diploid accessions with an S genome; DD: diploid accessions with a D genome.
Figure 2Amino acid substitution eliminates toxicity of known α-gliadin epitopes.
The DQ2-Glia-α3 epitope and the known 33-mer were synthesized in deamidated form either as the original sequence or after substitution in each epitope of the prolines at position 8 with serine. These peptides were tested in T cell proliferation assays. A: T cell proliferation assay using a DQ2-Glia-α3 T cell clone. B: T cell proliferation assay using a DQ2-Glia-α1 T cell clone. Positive control: synthetic peptide encoding the specific minimal T cell epitope. Stim. index: stimulation index defined as the specific proliferation of a sample divided by the background proliferation.
Figure 3Response of DQ2-Glia-α1 epitope specific T cell clones against single and multiple P to S substituted peptides.
Five T cell clones derived from 3 CD patients were tested against the deamidated form of the DQ2-Glia-α1 peptide (sequence PFPQPELPY) and variants thereof in which prolines at position 3, 5, 8 and 10 were systematically substituted for serine, both as single substitutions and in all possible combinations. Shown is the response to the substituted peptides relative to unsubstituted DQ2-Glia-α1 epitope. The introduced substitutions are underlined. The most C-terminal substituted proline at position 10 lies outside the 9 amino acid core of the T cell stimulatory peptide.